Product Description
Teva is developing Funapide as a treatment for postherpetic neuralgia. (Sourced from: https://clinicaltrials.gov/study/NCT02365636)
Mechanisms of Action: Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Bunion|Pain, Postoperative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FX301-2020-001 | P1 |
Completed |
Bunion|Pain, Postoperative |
2022-01-11 |
43% |